Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia.

NCT03962114 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT03962114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03962114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia.
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 18, 2019
Completion date
March 1, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ataxia telangiectasia, atm gene mutation